Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) yielded mixed results, sending shares down 57% in morning ...

We expect investors to focus on Altimmune’s ALT progress in the studies evaluating its lead pipeline candidate, pemvidutide, when it reports second-quarter 2025 results. Since ALT lacks a marketed ...

Altimmune Shares Rise on Liver Disease Trial Data Presentation Published: June 26, 2025 at 6:16 a.m. ET Share Resize ...

By Connor Hart Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for ...

--Altimmune, Inc., a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced financial results for the ...

Altimmune, Inc.'s top-line data from the phase 2b IMPACT study using pemvidutide for the treatment of patients with MASH expected in Q2 of 2025. The global non-alcoholic steatohepatitis [NASH ...

The Allegations: Rosen Law Firm is Investigating the Allegations that Altimmune, Inc. (NASDAQ: ALT) Misled Investors Regarding its Business Operations.

--Altimmune, Inc., a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the Company ...

Altimmune’s first quarter 2025 call underscored the company’s strategic progress, with the IMPACT Phase 2b NASH trial set to deliver data soon and new Phase 2 programs in alcohol-related liver ...

Altimmune shares jumped 8.5% on Friday. The stock is higher ahead of next week's presentation at the European Association for the Study of the Liver International Liver Congress.

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.

Over 30% of patients on pemvidutide 2.4 mg lost ≥ 20% body weight in the Phase 2 MOMENTUM trial. Pemvidutide cut liver fat by 76.4% at 24 weeks in a Phase 1b MASLD study, compared to 14% for ...